BARCLAYS PLC (BCS)
NYSEFinancialsBanks - DiversifiedSnapshot 2026-11-04
NYSEFinancialsBanks - DiversifiedSnapshot 2026-11-04
Research Workspace
Put BCS beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Financials is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Barclays' total revenue: Revenue: GBP 7.36B.
View ThesisModerate volatility — typically moves about 1% a day.
View RiskBarclays' revenue needs to stabilize to justify the price. The primary pillar is under pressure. Total revenue sits at GBP 7.36B. We lack recent earnings history to confirm a trend. The price is roughly in line with our growth forecast. We cannot anchor a clean multiple for this stock. The market cycle is currently in a Mania phase. Our model puts the next-quarter miss near 24%. Peer multiples imply a price about 18% below where it trades. This read is provisional. The thesis is on watch.
Trailing returns as of 2026-11-04. BCS is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 4 analysts currently covering BCS (as of Nov 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare BCS with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| BCS Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Financials (broad) — fair value, gap to price, and forward P/E.
Compare the value case
Put BCS next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Capital injection signals commitment to India growth.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Capital injection signals commitment to India growth.

Positive regulatory outcome for mis-sold car finance claims.

Regulatory remediation costs impact profitability and reputation.

Settlement deals confirm ongoing legal remediation costs.

Large payout confirms material liability and regulatory scrutiny.

Revolut's UK personal loans add competition for Barclays' consumer lending business.

Quarterly earnings transcript may inform outlook, but headline gives no results detail.
